medigraphic.com
ISSN 2221-2434 (Electronic)

2013, Number 2

<< Back

Finlay 2013; 3 (2)

Controversy about the se of beta-blockers for secondary prevention: critical analysis of the REACH registry

Morales SA, López MR, Vázquez SC

Language: Spanish
References: 21
Page: 134-137
PDF size: 64.71 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012). Rev Esp Cardiol. 2012 ; 65 (10): 937.e1-66.

  2. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 ; 308 (13): 1340-49.

  3. Morales Salinas A, Coca A. The β-blockers Crumbling Continues?: A critical analysis of the REACH Registry. The Ochsner journal. 2013 ; 13 (1): 167.

  4. Steg PG, Bhatt DL, Wilson PW, D Agostino R, Ohman EM, Röther J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007 ; 297 (11): 1197-1206.

  5. Alberts MJ, Bhatt DL, Mas JL, Ohman M, Hirsch AT, Röther J, et al. Three-year follow-up and event rates in the international REreduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009 ; 30 (19): 2318-26.

  6. Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. JAMA. 2010 ; 304 (12): 1350-57.

  7. Lao O, Dupanloup I, Barbujani G, Bertranpetit J, Calafell F. The Mediterranean Paradox for Susceptibility Factors in Coronary Heart Disease Extends to Genetics. Ann Hum Genet. 2008 ; 72: 48-56.

  8. Wilson PW, D Agostino RB, Levy D, Belanguer AM, Silvershatz H, kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 ; 97 (18): 1837-47.

  9. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006 ; 333 (7578): 1091-4.

  10. Webb AJS, Fischer URS, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010 ; 375 (9718): 906-15.

  11. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009 ; 27 (11): 2121-58.

  12. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 ; 359 (9311): 995-1003.

  13. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield m, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 ; 366 (9489): 895-906.

  14. Morales Salinas A. Atenolol in uncomplicated hypertension: time for changes. The Lancet Neurology. 2010 ; 9 (7): 652.

  15. Neutel JM, Schnaper H, Cheung DG, Graettinger WF, Weber MA. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J. 1990 ; 120 (1): 166-71.

  16. Wolfgang C, Winkelmayer WC, Kurth T. Propensity scores: help or hype?. Nephrol Dial Transplant. 2004 ; 19 (7): 1671-3.

  17. Morales Salinas A. Variabilidad en la medida de presión arterial periférica. ¿Limitación o marcador de riesgo?. Hipertens Riesgo Vasc. 2012 ; 29 (2): 50-1.

  18. Morales Salinas A. Comentarios a la nueva guía de hipertensión arterial de la Sociedad Española de Hipertensión”. Hipertensión. 2005 ; 22 (9): 366-7.

  19. Morales Salinas A. Dogmas y actualidades del uso de los beta-bloqueadores en prevención secundaria. Primera parte. Revista Finlay [revista en Internet]. 2011 [ cited 13 May 2013 ] ; 1 (2): [aprox. 3p]. Available from: http://www.revfinlay.sld.cu/index.php/finlay/articl e/view/47/143.

  20. Morales Salinas A. Dogmas y actualidades del uso de los beta-bloqueadores en prevención secundaria. Segunda parte. Revista Finlay [revista en Internet]. 2012 [ cited 13 May 2013 ] ; 2 (1): [aprox. 2p]. Available from: http://www.revfinlay.sld.cu/index.php/finlay/articl e/view/97.

  21. Morales Salinas A. Los beta-bloqueadores como primera opción del tratamiento en la hipertensión no complicada ¿posible o no?. Revista Finlay [revista en Internet]. 2011 [ cited 13 May 2013 ] ; 1 (1): [aprox. 8p]. Available from: http://www.revfinlay.sld.cu/index.php/finlay/articl e/view/27/127.




2020     |     www.medigraphic.com